{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:24Z","timestamp":1793383164817,"version":"4.5.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:label\/>\n                  <jats:p>World-wide, emerging triazole resistance increasingly complicates treatment of invasive aspergillosis (IA). In settings with substantial (&amp;gt;10%) prevalence of triazole resistance, empiric combination therapy with both a triazole and liposomal amphotericin B (LAmB) can be considered because of the low yields of susceptibility testing. To avoid toxicity while optimizing outcome, a strategy with monotherapy would be preferable. A newly designed treatment algorithm based on literature and expert consensus provided guidance for empiric monotherapy with either voriconazole or LAmB. Over a four and a half year period, all adult patients in our hospital treated for IA were included and patient data were collected. An independent committee reviewed the attributability of death to IA for each patient. Primary outcomes were 30- and 100-day crude mortality and attributable mortality. In total, 110 patients were treated according to the treatment algorithm. Fifty-six patients (51%) were initially treated with voriconazole and 54 patients (49%) with LAmB. Combined attributable and contributable mortality was 13% within 30 days and 20% within 100 days. Treatment switch to LAmB was made in 24\/56 (43%) of patients who were initially treated with voriconazole. Combined contributable and attributable 100-day mortality in this subgroup was 21% and was not increased when compared with patients initially treated with LAmB (P\u00a0=\u00a00.38). By applying a comprehensive clinical decision algorithm, an antifungal-sparing regime was successfully introduced. Further research is warranted to explore antifungal treatment strategies that account for triazole-resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Lay summary<\/jats:title>\n                  <jats:p>Due to resistance of Aspergillus against triazoles, combination therapy with liposomal amphotericin B (LAmB) is applied more often as primary therapy against invasive aspergillosis. This study presents the results of a decision tool which differentiated between triazole or LAmB monotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mmy\/myab060","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T20:13:40Z","timestamp":1637266420000},"source":"Crossref","is-referenced-by-count":3,"title":["Implementation of a clinical decision rule for selecting empiric treatment for invasive aspergillosis in a setting with high triazole resistance"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9527-2268","authenticated-orcid":false,"given":"Robert J","family":"van de Peppel","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Leiden University Medical Center, 2333ZA Leiden, the Netherlands"},{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"van Grootveld","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J C","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"van Paassen","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Leiden University Medical Center, 2333ZA Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Bernards","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetty","family":"Jolink","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Leiden University Medical Center, 2333ZA Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia G","family":"Koopmans","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A","family":"von dem Borne","sequence":"additional","affiliation":[{"name":"Department of Haematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha T","family":"van der Beek","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G J","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Leiden University Medical Center, 2333ZA Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"2021120812115854300_bib1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of america","volume":"63","author":"Patterson","year":"2016","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"2021120812115854300_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"2021120812115854300_bib3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"4 Suppl 1","author":"Ullmann","year":"2018","journal-title":"Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"key":"2021120812115854300_bib4","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/jac\/dkv177","article-title":"High prevalence of azole resistance in aspergillus fumigatus isolates from high-risk patients","volume":"70","author":"Fuhren","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021120812115854300_bib5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.cmi.2018.11.027","article-title":"Triazole resistance in aspergillus fumigatus: recent insights and challenges for patient management","volume":"25","author":"Lestrade","year":"2019","journal-title":"Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"key":"2021120812115854300_bib6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jac\/dky517","article-title":"Emerging threat of triazole-resistant aspergillus fumigatus","volume":"74","author":"Rybak","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021120812115854300_bib7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1473-3099(09)70265-8","article-title":"Azole resistance in aspergillus fumigatus: a side-effect of environmental fungicide use?","volume":"9","author":"Verweij","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2021120812115854300_bib8","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3201\/eid1710.110226","article-title":"Clinical implications of azole resistance in aspergillus fumigatus, the netherlands, 2007\u20132009","volume":"17","author":"van der Linden","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2021120812115854300_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant aspergillus fumigatus","volume":"21-22","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2021120812115854300_bib10","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin b as initial therapy for invasive mold infection: a randomized trial comparing a high loading-dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"2021120812115854300_bib11","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1086\/521942","article-title":"Comparison of 2 studies of treatment of invasive aspergillosis","volume":"45","author":"Denning","year":"2007","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"2021120812115854300_bib12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin b for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2021120812115854300_bib13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/cid\/ciu911","article-title":"Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin b for therapy of invasive aspergillosis: a collaborative study of the mycoses study group (MSG 05) and the european organization for research and treatment of cancer infectious diseases group","volume":"60","author":"Herbrecht","year":"2015","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"2021120812115854300_bib14","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1093\/cid\/ciz064","article-title":"Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B","volume":"68","author":"Adler-Moore","year":"2019","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"2021120812115854300_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/mmy\/myw114","article-title":"Invasive aspergillosis in acute myeloid leukemia: are we making progress in reducing mortality?","volume":"55","author":"Dragonetti","year":"2017","journal-title":"Med Mycol"},{"key":"2021120812115854300_bib16","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1093\/cid\/ciz076","article-title":"Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B","volume":"68","author":"Groll","year":"2019","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"2021120812115854300_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jiac.2018.04.014","article-title":"The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B","volume":"24","author":"Kato","year":"2018","journal-title":"Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy"},{"key":"2021120812115854300_bib18","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","author":"Marr","year":"2002","journal-title":"Blood"},{"key":"2021120812115854300_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/cid\/ciu337","article-title":"Immune correlates of protection in human invasive aspergillosis","volume":"59","author":"Camargo","year":"2014","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"2021120812115854300_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/tid.12060","article-title":"Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience","volume":"15","author":"Neofytos","year":"2013","journal-title":"Transplant infectious disease: an official journal of the Transplantation Society"},{"key":"2021120812115854300_bib21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/mmy\/myu036","article-title":"Relapsed and secondary disease drive the risk profile for invasive aspergillosis prior to stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome","volume":"52","author":"van de Peppel","year":"2014","journal-title":"Med Mycol"},{"key":"2021120812115854300_bib22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3324\/haematol.2009.012054","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study","volume":"95","author":"Pagano","year":"2010","journal-title":"Haematologica"},{"key":"2021120812115854300_bib23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jinf.2018.02.012","article-title":"The burden of invasive aspergillosis in patients with haematological malignancy: a meta-analysis and systematic review","volume":"76","author":"van de Peppel","year":"2018","journal-title":"J Infect"},{"key":"2021120812115854300_bib24","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks Btk-dependent NF-kB and NFAT responses in human macrophages during aspergillus fumigatus phagocytosis","volume":"132","author":"Bercusson","year":"2018","journal-title":"Blood"},{"key":"2021120812115854300_bib25","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"2021120812115854300_bib26","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1371\/journal.pmed.0050219","article-title":"Emergence of azole resistance in aspergillus fumigatus and spread of a single resistance mechanism","volume":"5","author":"Snelders","year":"2008","journal-title":"PLoS Med"},{"key":"2021120812115854300_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00019-17","article-title":"Global population genetic analysis of aspergillus fumigatus","volume":"2","author":"Ashu","year":"2017","journal-title":"mSphere"},{"key":"2021120812115854300_bib28","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3389\/fmicb.2015.00428","article-title":"Prevalence and mechanism of triazole resistance in aspergillus fumigatus in a referral chest hospital in delhi, india and an update of the situation in asia","volume":"6","author":"Chowdhary","year":"2015","journal-title":"Frontiers in microbiology"},{"key":"2021120812115854300_bib29","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/jac\/dkx168","article-title":"Isolation of azole-resistant aspergillus fumigatus from the environment in the south-eastern USA","volume":"72","author":"Hurst","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021120812115854300_bib30","doi-asserted-by":"crossref","first-page":"570 e1\u20139","DOI":"10.1016\/j.cmi.2016.04.001","article-title":"Azole-resistant aspergillus fumigatus in denmark: a laboratory-based study on resistance mechanisms and genotypes","volume":"22","author":"Jensen","year":"2016","journal-title":"Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"key":"2021120812115854300_bib31","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3201\/eid2009.140142","article-title":"Passive surveillance for azole-resistant aspergillus fumigatus, united states, 2011\u20132013","volume":"20","author":"Pham","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2021120812115854300_bib32","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2021120812115854300_bib33"},{"key":"2021120812115854300_bib34","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1093\/jac\/dkw323","article-title":"PCRbased detection of aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the aspergenius assay(R) in 201 patients with haematological disease suspected for invasive aspergillosis","volume":"71","author":"Chong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021120812115854300_bib35","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1128\/JCM.01032-17","article-title":"Molecular diagnosis of invasive aspergillosis and detection of azole resistance by a newly commercialized PCR kit","volume":"55","author":"Dannaoui","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2021120812115854300_bib36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jinf.2017.11.011","article-title":"Improving the diagnosis of invasive aspergillosis by the detection of aspergillus in broncho-alveolar lavage fluid: comparison of non-culture-based assays","volume":"76","author":"Guegan","year":"2018","journal-title":"J Infect"},{"key":"2021120812115854300_bib37","article-title":"SWAB guidelines for the management of invasive fungal infections","author":"SIFIG","year":"2017"},{"key":"2021120812115854300_bib38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijantimicag.2018.10.021","article-title":"Managing invasive aspergillosis in hematologichematological patients in the era of resistance polymerase chain reaction and increasing triazole resistance: a modelling study of different strategies","volume":"53","author":"van de Peppel","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2021120812115854300_bib39","first-page":"CD010481","article-title":"Amphotericin b deoxycholate versus liposomal amphotericin B: effects on kidney function","author":"Botero Aguirre","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2021120812115854300_bib40","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the european organization for research and treatment of cancer\/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC\/MSG) consensus group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"2021120812115854300_bib41","doi-asserted-by":"crossref","first-page":"e0120370","DOI":"10.1371\/journal.pone.0120370","article-title":"Causes of death in a contemporary cohort of patients with invasive aspergillosis","volume":"10","author":"Garcia-Vidal","year":"2015","journal-title":"PLoS One"},{"key":"2021120812115854300_bib42","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jphp.12802","article-title":"Efficacy and safety of amphotericin b formulations: a network meta-analysis and a multicriteria decision analysis","volume":"69","author":"Tonin","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"2021120812115854300_bib43","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"2021120812115854300_bib44","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the british society for medical mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2021120812115854300_bib45","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fmicb.2018.00555","article-title":"Comparison of two molecular assays for detection and characterization of aspergillus fumigatus triazole resistance and Cyp51A mutations in clinical isolates and primary clinical samples of immunocompromised patients","volume":"9","author":"Postina","year":"2018","journal-title":"Frontiers in Microbiology"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/60\/1\/myab060\/41646729\/myab060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/60\/1\/myab060\/41646729\/myab060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T12:24:54Z","timestamp":1638966294000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myab060\/6433628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,11,23]]},"published-print":{"date-parts":[[2021,12,8]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myab060","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1]]},"published":{"date-parts":[[2021,11,23]]},"article-number":"myab060"}}